This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Brainsway is happy to announce new coverage with Excellus BC/BS, effective immediately. This decision will now provide an additional 1.55 million patients in New York with access to the latest Deep TMS depression treatment.
We are equally pleased to announce that Blue Cross/ Blue Shield Mississippi has included coverage for Brainsway’s Deep TMS treatment as well. This new coverage will allow over 600,000 patients living in Mississippi to have access to Deep TMS to help beat their depression.